About: Proper Management of People with Obesity during the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proper Management of People with Obesity during the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Proper Management of People with Obesity during the COVID-19 Pandemic
Creator	Lim, Soo Jung, Chang Koo, Bo Nam, Ga Shin, Soo
source	Medline; PMC
abstract	Since December 2019, countries around the world have been struggling with a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Case series have reported that people with obesity experience more severe coronavirus disease 2019 (COVID-19). During the COVID-19 pandemic, people have tended to gain weight because of environmental factors imposed by quarantine policies, such as decreased physical activity and increased consumption of unhealthy food. Mechanisms have been postulated to explain the association between COVID-19 and obesity. COVID-19 aggravates inflammation and hypoxia in people with obesity, which can lead to severe illness and the need for intensive care. The immune system is compromised in people with obesity and COVID-19 affects the immune system, which can lead to complications. Interleukin-6 and other cytokines play an important role in the progression of COVID-19. The inflammatory response, critical illness, and underlying risk factors may all predispose to complications of obesity such as diabetes mellitus and cardiovascular diseases. The common medications used to treat people with obesity, such as glucagon-like peptide-1 analogues, statins, and antiplatelets agents, should be continued because these agents have anti-inflammatory properties and play protective roles against cardiovascular and all-cause mortality. It is also recommended that renin–angiotensin system blockers are not stopped during the COVID-19 pandemic because no definitive data about the harm or benefits of these agents have been reported. During the COVID-19 pandemic, social activities have been discouraged and exercise facilities have been closed. Under these restrictions, tailored lifestyle modifications such as home exercise training and cooking of healthy food are encouraged.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.7570/jomes20056
bibo:pmid	32544885
has license	cc-by-nc
sha1sum (hex)	42a12f7b7ed32ac12e4cefa5bb4e0ff61489b03d
schema:url	https://doi.org/10.7570/jomes20056
resource representing a document's title	Proper Management of People with Obesity during the COVID-19 Pandemic
has PubMed Central identifier	PMC7338495
has PubMed identifier	32544885
schema:publication	J Obes Metab Syndr
resource representing a document's body	covid:42a12f7b7ed32ac12e4cefa5bb4e0ff61489b03d#body_text
is schema:about of	named entity 'quarantine' named entity 'obesity' named entity 'risk factor' named entity 'ACE2' named entity 'COVID-19 pandemic' named entity 'TNF-α' named entity 'obesity' named entity 'vildagliptin' named entity 'macrophages' named entity 'coronavirus' named entity 'tumor necrosis factor α' named entity 'COVID-19' named entity 'COVID-19' named entity 'hamburgers' named entity 'NF-κB' named entity 'insulin sensitivity' named entity 'Liraglutide' named entity 'Obesity' named entity 'RAAS' named entity 'Health-care' named entity 'ischemia' named entity 'Obesity' named entity 'chronic inflammation' named entity 'sputum' named entity 'GLP1' named entity 'obesity' named entity 'weight gain' named entity 'nonalcoholic fatty liver disease' named entity 'prognosis' named entity 'hyperinsulinemia' named entity 'RAS' named entity 'healthy food' named entity 'TNF-α' named entity 'MCP1' named entity 'downregulated' named entity 'hypertrophic' named entity 'catalytic domain' named entity 'LDL receptor' named entity 'ACE2' named entity 'gaining weight' named entity 'blood pressure' named entity 'ACE2' named entity 'TNF-α' named entity 'DPP4' named entity 'MCP1' named entity 'fat' named entity 'blood pressure' named entity 'obesity' named entity 'GLP1' named entity 'angiotensin' named entity 'endothelium' named entity 'SARS-CoV-2' named entity 'CRP' named entity 'COVID-19' named entity 'COVID' named entity 'CVD' named entity 'neutrophil' named entity 'multiorgan failure' named entity 'respiratory diseases' named entity 'spike protein' named entity 'cytokine' named entity 'immune function' named entity 'hypertension' named entity 'adipose tissue' named entity 'organ' named entity 'Regular exercise' named entity 'exposure to the virus' named entity 'receptor' named entity 'GLP1' named entity 'obesity' named entity 'inflammatory cytokines' named entity 'endocrine pancreas' named entity 'hepatic' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'anti-inflammatory' named entity 'cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software